Poor
Mostly Aligned
Patient Risk:
Moderate
Summary
Overall alignment is poor. The provided claims largely omit or misstate key prescribing information; only a subset of mechanistic and some dosing-related statements are supported, while many safety, indications, and pediatric considerations are absent. There is one contradicted statement (claim 14) that conflicts with the label. Substantial safety and usage content appears to be missing.
Category Scores
Accurate Statements
Tramadol binds mu-opioid receptors (weakly).
12.1
Tramadol inhibits serotonin reuptake.
12.1
Tramadol inhibits norepinephrine reuptake.
12.1
Tramadol is an opioid agonist and inhibits reuptake of norepinephrine and serotonin; the analgesic activity involves both parent and M1 metabolite mu-receptor binding.
12.1
Unsupported Statements
Tramadol and codeine are both opioid analgesics that relieve moderate pain.
The label does not present tramadol and codeine as interchangeable with a generalized indication of “moderate pain.” Indication content is not supported by the provided label text.
The combination of mu-binding and SNRI effects adds an antidepressant-like effect for tramadol.
Not supported by the label content provided.
Codeine acts primarily as a prodrug converted by liver enzyme CYP2D6 to morphine for its full opioid effect.
Not supported by the provided label content.
Clinical studies show similar efficacy for acute postoperative pain between tramadol and codeine.
Not supported by the provided label content.
Clinical studies show similar efficacy for chronic conditions like osteoarthritis between tramadol and codeine.
Not supported by the provided label content.
Tramadol matches codeine's relief at comparable doses (e.g., 50-100 mg tramadol vs. 30-60 mg codeine).
Not supported by the provided label content.
Tramadol may edge out in neuropathic pain due to its neurotransmitter action.
Not supported by the provided label content.
Tramadol is generally considered stronger than codeine because of its additional non-opioid pathway.
Not supported by the provided label content.
Tramadol requires lower doses for equivalent analgesia in some patients.
Not supported by the provided label content.
Codeine effect varies based on CYP2D6 genetics—ultra-rapid metabolizers get excessive morphine, while poor metabolizers get little relief.
Not supported by the provided label content.
Tramadol's effects are less genetically variable.
Not supported by the provided label content.
Potency: Tramadol is moderate (weaker mu-binding + SNRI).
Not supported by the provided label content.
Potency: Codeine is weak (relies on conversion to morphine).
Not supported by the provided label content.
Onset: Tramadol is about 1 hour.
Not supported by the provided label content.
Onset: Codeine is about 0.5-1 hour.
Not supported by the provided label content.
Duration: Tramadol about 4-6 hours.
Not supported by the provided label content.
Duration: Codeine about 4 hours.
Not supported by the provided label content.
Common side effects include nausea.
Not consistently mapped to the label’s adverse reaction listing in the provided data.
Common side effects include dizziness.
Not consistently mapped to the label’s adverse reaction listing in the provided data.
Common side effects include constipation.
Not consistently mapped to the label’s adverse reaction listing in the provided data.
Common side effects include sedation.
Not consistently mapped to the label’s adverse reaction listing in the provided data.
Tramadol adds risks of seizures (especially at high doses or with antidepressants).
Not consistently mapped to the label’s seizure/5.10 section in the provided data.
Tramadol adds risk of serotonin syndrome.
Not consistently mapped to the label’s 5.9 section in the provided data.
Codeine risks respiratory depression in children and overdose in rapid metabolizers, leading to FDA warnings against pediatric use.
Not consistently mapped to the label’s warnings for pediatric use in the provided data.
Withdrawal is similar for both tramadol and codeine.
Not consistently mapped to the label’s withdrawal discussion in the provided data.
Physicians often substitute one for the other in opioid rotation, starting at equivalent doses.
Not supported by the provided label content.
Contradictions
Low
AI Statement
Tramadol matches codeine's relief at comparable doses (e.g., 50-100 mg tramadol vs. 30-60 mg codeine).
Label Reference
5.6
Important Omissions
Contraindications and boxed warnings are not fully addressed for the specific tramadol extended-release formulation.
Importance:
High
Pediatric safety and use in specific pediatric populations (8.4, pediatric use) are not adequately covered by the claims.
Importance:
High
Drug interactions, monitoring recommendations, and detailed adverse reactions are not comprehensively covered.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Significant omissions in indication, contraindications, boxed warnings, and pediatric safety, along with a contradicted statement, raise safety concerns about translation of claims to labeling.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Substantial omissions and a contradiction (claim 14) weaken alignment with label; add missing contraindications, boxed warnings, pregnancy/pediatric content, and ensure consistency with 5.x warnings.
Suggested Improvement
Reconcile conflicting statements (e.g., claim 14 vs. 5.6). Expand coverage of indications, contraindications, boxed warnings, drug interactions, use in specific populations (pediatrics, geriatrics), adverse reactions, monitoring, and administration instructions.